Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up.
about
Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantationLamivudine or adefovir dipivoxil for preventing hepatitis B recurrence after liver transplantationManagement of HBV Infection in Liver Transplantation PatientsKASL clinical practice guidelines: management of chronic hepatitis BChange of strategies and future perspectives against hepatitis B virus recurrence after liver transplantationTreatment of chronic hepatitis.Clinicopathological features of hepatitis B virus recurrence after liver transplantation: eleven-year experience.Prevention of fungal and hepatitis virus infections in liver transplantation.Hepatitis B and C in the liver transplant recipient: current understanding and treatment.A concise update on the status of liver transplantation for hepatitis B virus: the challenges in 2002.Treatment of hepatitis B and C after liver transplantation. Part 1, hepatitis B.KASL Clinical Practice Guidelines: Management of chronic hepatitis B.Prevention and treatment of recurrent Hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analoguesReview article: hepatitis B and liver transplantation.Prevention of hepatitis B virus recurrence after liver transplantation.Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation.Hepatitis B immunoglobulins and/or lamivudine for preventing hepatitis B recurrence after liver transplantation: a systematic review.Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation.HBIG Remains Significant in the Era of New Potent Nucleoside Analogues for Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation.Rational Basis for Optimizing Short and Long-term Hepatitis B Virus Prophylaxis Post Liver Transplantation: Role of Hepatitis B Immune Globulin.Current clinical evidence for nucleos(t)ide analogues in patients with HBV-related hepatocellular carcinoma.Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: Results up to 8 years.Comparative efficacy of oral nucleotide analogues for the prophylaxis of hepatitis B virus recurrence after liver transplantation: a network meta-analysis.Efficacy and tolerability of Entecavir for hepatitis B virus infection after hematopoietic stem cell transplantation.Management of HBV infection during immunosuppressive treatmentClinical-pathological analysis of hepatitis B virus recurrence after liver transplantation in Chinese patients.Different effect of HBV vaccine after liver transplantation between chronic HBV carriers and non-HBV patients who received HBcAb-positive grafts.Lamivudine for hepatitis B after liver transplantation.Beneficial effect of lamivudine for hepatitis B transplant recipients.Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis.The long-term efficacy of nucleos(t)ide analog plus a year of low-dose HBIG to prevent HBV recurrence post-liver transplantation.No hepatitis recurrence using combination prophylaxis in HBV-positive liver transplant recipients with YMDD mutants.HBV vaccination in liver transplant recipients: not an effective strategy in the prophylaxis of HBV recurrence.Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B.Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance.Significance of hepatitis B virus genotype in liver transplantation for chronic hepatitis B.
P2860
Q24234338-65B6832E-2284-4F9C-A44B-731786CE6606Q24244437-E98DFD81-9096-46B0-8F19-B1336D282EE9Q24529103-207E3982-ECA3-4DCA-9CBE-DA403C4E3DD8Q26752475-7CBC06D8-E81A-4836-9CDC-C4730E2866E4Q26784241-B9EA101D-C530-4719-9110-F76366FCFBC3Q28364240-3C5C52CA-8E67-44C6-BE56-8DB076C8841DQ34029115-4EAE77AC-74FB-425B-BA68-BAF95B8331ABQ34271696-1BFE0178-FE4E-4715-A25E-F6C22650BAB3Q34426421-C925959D-644D-453B-9536-3AE9B301A6BDQ34499694-C946CE7A-9E02-448F-8F56-2F47DAC67E5AQ36028324-8253DC4E-C2EC-4857-8647-8E0F32A4F1CCQ36153966-02DBD1B3-AEDE-4681-BCC9-AA6513C9B7A7Q36442537-23FAF981-A506-4C66-9C40-B9537D98E93EQ36447557-2A836D8B-ADD0-4D08-8A85-830519D158F3Q36652077-F21EE534-BA0F-4830-90F6-B71B1DC77C74Q37495757-C5D2BD0C-BB20-413F-B956-38816A04A99BQ37764964-44619F76-8A49-4FAC-B5B3-F778B9E0FDF7Q38177252-C42A4172-ABC8-403B-B4CA-B83EF0CA6B5AQ38218762-4A4BA1BB-AAD7-4B74-96ED-41A61291ECACQ38514411-3164B238-3516-4FCE-AAAF-31FD0EEBCC3EQ38665203-93910C6E-A7EA-41FB-B579-917C130B2E66Q40261285-F071AEE5-81F5-4E76-BCF2-A5E74B466635Q40588229-38A51648-6F01-42F5-81C0-9E560B0D278EQ41756602-AA7008C5-D9B6-4FB6-B4DF-39DBFD9E940BQ41859437-96F28426-867F-41AC-A0D8-5BA480274150Q42244681-1E26F4D5-4101-4568-8F43-B6746A1C62BDQ43640407-E4E1DB1C-A9C6-4747-80C1-664038B34D0FQ43666869-71F36B98-11D0-42B7-BF1E-2C8C77C252E2Q43988925-AB9462C3-05EA-41D6-8517-81B4CCE85437Q44124730-604159DE-77D7-47D7-9275-1040C60BD584Q44254904-123A68C1-55F1-479F-BA0B-FA193047E8CDQ44425133-785E9D54-C207-4E9D-A0E3-5AA9AD02CBCAQ45250862-48B38369-8D80-44AC-A15C-4202B3287F54Q45273548-2702BF16-6BD5-4A9C-9687-E205902F1CDAQ45299212-12DDB65D-874D-4612-93C7-F96EA618AFEDQ45365708-7A39FDC6-CA60-469D-9CF8-AFC3E380C677Q45438761-AE222CC8-2813-4E4E-8A69-577344764D54
P2860
Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Lamivudine without HBIg for pr ...... atitis B: long-term follow-up.
@ast
Lamivudine without HBIg for pr ...... atitis B: long-term follow-up.
@en
type
label
Lamivudine without HBIg for pr ...... atitis B: long-term follow-up.
@ast
Lamivudine without HBIg for pr ...... atitis B: long-term follow-up.
@en
prefLabel
Lamivudine without HBIg for pr ...... atitis B: long-term follow-up.
@ast
Lamivudine without HBIg for pr ...... atitis B: long-term follow-up.
@en
P2093
P1433
P1476
Lamivudine without HBIg for pr ...... atitis B: long-term follow-up.
@en
P2093
Anschuetz G
Burroughs A
Dhillon AP
Dusheiko G
Grellier L
Hubscher S
P304
P356
10.1097/00007890-200009150-00018
P577
2000-09-01T00:00:00Z